Connective tissue diseases: Targeting type I interferon in systemic lupus erythematosus.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

1. Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review.Frontiers in immunology · 2022
   Pooled it
2. Dangers of Herpesvirus Infection in SLE Patients Under Anifrolumab Treatment: Case Reports and Clinical Implications.The American journal of case reports · 2024
   Article
3. Circulating mitochondrial DNA copy numbers represent a sensitive marker for diagnosis and monitoring of disease activity in systemic lupus erythematosus.RMD open · 2021
   Article
4. FcγRIIA expression accelerates nephritis and increases platelet activation in systemic lupus erythematosus.Blood · 2020
   Article
5. Type I interferon in the pathogenesis of systemic lupus erythematosus.Current opinion in immunology · 2020
   Review
6. Lessons from precision medicine in rheumatology.Multiple sclerosis (Houndmills, Basingstoke, England) · 2020
   Review
7. Protein and DNA methylation-based scores as surrogate markers for interferon system activation in patients with primary Sjögren's syndrome.RMD open · 2020
   Article
8. Type I Interferon Predicts an Alternate Immune System Phenotype in Systemic Lupus Erythematosus.ACR open rheumatology · 2019
   Article
9. Insights from deconvolution of cell subtype proportions enhance the interpretation of functional genomic data.PloS one · 2019
   Article
10. Type I interferon in rheumatic diseases.Nature reviews. Rheumatology · 2018
    Review
11. Elevated serum levels of IL-6 and CXCL9 in autoimmune retinopathy (AIR) patients.Journal of neuroimmunology · 2018
    Article
12. Defining biological subsets in systemic lupus erythematosus: progress toward personalized therapy.Pharmaceutical medicine · 2017
    Article

Corrections and comments

• Comment on
  Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.2016

Authors and funding

1 author at 1 institution in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as